Q2 revenue rose 5% to $16.6B, led by oncology, animal health, and new launches. Guidance for 2026 was raised, with EPS expected at $2.66–$2.76, including a one-time Terns charge. Multiple regulatory approvals and pipeline advances de-risk future growth.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.